SUMO inhibitors with SUMO-unconjugated TFAP2A reduce the cancer stem cell (CSC) population by suppressing CD44 and matrix metallopeptidase 14 (MMP14) expression to limit the stemness [43–45]. This evidence concerns the gene TFAP2A and cancer.